Ziopharm Oncology Inc. (NASDAQ:ZIOP)’s share price rose 4.8% during trading on Tuesday . The stock traded as high as $6.12 and last traded at $5.93, with a volume of 1,807,898 shares trading hands. The stock had previously closed at $5.66.

ZIOP has been the topic of several research reports. Wells Fargo & Co. raised Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a research report on Wednesday, August 10th. Zacks Investment Research raised Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Tuesday, August 16th. Griffin Securities reaffirmed a “buy” rating and issued a $21.00 target price on shares of Ziopharm Oncology in a research report on Monday, August 15th. Raymond James Financial Inc. initiated coverage on Ziopharm Oncology in a research report on Thursday, June 2nd. They issued a “market perform” rating on the stock. Finally, Mizuho reaffirmed a “neutral” rating and issued a $5.00 target price (down previously from $7.00) on shares of Ziopharm Oncology in a research report on Monday, July 18th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Ziopharm Oncology presently has a consensus rating of “Buy” and a consensus target price of $9.75.

The stock has a 50 day moving average price of $5.32 and a 200 day moving average price of $6.57. The company’s market cap is $763.40 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ziopharm-oncology-inc-ziop-stock-price-up-4-8.html

Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.52 million. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. Ziopharm Oncology’s revenue for the quarter was up 525.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) EPS. On average, analysts forecast that Ziopharm Oncology Inc. will post ($1.34) EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Fox Run Management L.L.C. purchased a new position in Ziopharm Oncology during the second quarter valued at approximately $133,000. Creative Planning boosted its position in Ziopharm Oncology by 185.1% in the second quarter. Creative Planning now owns 30,864 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 20,040 shares in the last quarter. Royal Bank of Canada boosted its position in Ziopharm Oncology by 6.4% in the first quarter. Royal Bank of Canada now owns 16,189 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 974 shares in the last quarter. LPL Financial LLC boosted its position in Ziopharm Oncology by 60.3% in the first quarter. LPL Financial LLC now owns 40,210 shares of the biotechnology company’s stock valued at $311,000 after buying an additional 15,132 shares in the last quarter. Finally, A.R.T. Advisors LLC purchased a new position in Ziopharm Oncology during the first quarter valued at approximately $1,732,000. 44.95% of the stock is currently owned by hedge funds and other institutional investors.

Ziopharm Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

5 Day Chart for NASDAQ:ZIOP

Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.